24/02/21 |
UK-RTC statement on AbC-19TM rapid antibody test |
19/02/21 |
Director/PDMR Shareholding, Exercise of Options and Total Voting Rights |
18/02/21 |
Director/PDMR Shareholding, Exercise of Options and Total Voting Rights |
16/02/21 |
AbC-19TM rapid antibody test performance data |
15/02/21 |
Director/PDMR Shareholding, Exercise of Options and Total Voting Rights |
11/02/21 |
UK Government manufacturing contract. Board appointment & trading update |
11/02/21 |
Directorate Change |
08/02/20 |
Statement re. media comment |
02/02/21 |
Exercise of Options and Total Voting Rights |
28/01/21 |
Exercise of Options and Total Voting Rights |
26/01/21 |
Update re AbC-19TM Rapid Test & Launch of COVID-19 antibody laboratory-based testing service |
26/01/21 |
Launch of COVID-19 antibody laboratory-based testing service |
22/01/21 |
Exercise of Options and Total Voting Rights |
11/01/21 |
Exercise of Options and Total Voting Rights |
29/12/20 |
Update re AbC-19TM Rapid Test |
24/12/20 |
Mologic CE Mark Rapid Antigen Test |
11/12/20 |
Exercise of Options and Total Voting Rights |
07/12/20 |
Exercise of Options and Total Voting Rights |
02/10/20 |
Director/PDMR Shareholding |
30/11/20 |
Exercise of Options and Total Voting Rights |
30/11/20 |
Interim Results - Six months ended 30 September 2020 |
23/11/20 |
Exercise of Options and Total Voting Rights |
17/11/20 |
UK-RTC Update |
16/11/20 |
Holding(s) in Company |
16/11/20 |
Holding(s) in Company |
13/11/20 |
Exercise of Options and Total Voting Rights |
12/11/20 |
UK-RTC Statement |
12/11/20 |
Response to media comment |
11/11/20 |
Investor presentation – Q&A Update |
09/11/20 |
Exercise of Options and Total Voting Rights |
06/11/20 |
Exercise of Options and Total Voting Rights |
03/11/20 |
Chinese approval for self-test use of Food Detective® test |
30/10/20 |
Exercise of Options and Total Voting Rights |
29/10/20 |
Notification of Major Holdings |
28/10/20 |
Trading update and notice of interim results |
20/10/20 |
Notice of Trading Update and Investor Presentation |
20/10/20 |
Exercise of Options and Total Voting Rights |
19/10/20 |
UK-RTC contract for the Supply of Goods |
14/10/20 |
Exercise of Options and Total Voting Rights |
09/10/20 |
Exercise of Options and Total Voting Rights |
06/10/20 |
Notification of Major Holdings |
06/10/20 |
UK Government contract for UK-Rapid Test Consortium |
02/10/20 |
Preliminary report published by Ulster University |
15/09/20 |
TR-1: Standard form for notification of major holdings |
14/09/20 |
Exercise of Options and Total Voting Rights |
07/09/20 |
Statement regarding Share Price Movement |
07/09/20 |
Completion of self-test usability study for AbC-19™ Rapid test |
03/09/20 |
CE-Mark for Mologic COVID-19 antibody test |
01/09/20 |
Exercise of Options and Total Voting Rights |
26/08/20 |
Result of Annual General Meeting |
26/08/20 |
Exercise of Options and Total Voting Rights |
24/08/20 |
Exercise of Options and Total Voting Rights |
21/08/20 |
WHO Prequalification Received |
30/07/20 |
Update on progress of UK-Rapid Test Consortium |
24/07/20 |
Exercise of Options and Total Voting Rights |
23/07/20 |
Notice of AGM and posting of Annual Report |
20/07/20 |
Investor Presentation |
14/07/20 |
Final Results - Year Ended 31 March 2020 |
10/07/20 |
Result of General Meeting |
10/07/20 |
Notice of Results |
08/07/20 |
Result of Open Offer |
02/07/20 |
COVID-19 ELISA - Approval for sale in India |
29/06/20 |
Update on progress of UK-Rapid Test Consortium - Design Freeze |
22/06/20 |
Publication of Shareholder Circular |
22/06/20 |
Investor presentation |
19/06/20 |
Fundraising to raise gross proceeds of up to £11m |
09/06/20 |
Trading Update |
03/06/20 |
Update on progress of UK-Rapid Test Consortium |
01/06/20 |
Holdings in Company |
27/05/20 |
Statement regarding share price movement |
22/05/20 |
Exercise of Options and Total Voting Rights |
07/05/20 |
Exercise of Options and Total Voting Rights |
04/05/20 |
Exercise of Options and Total Voting Rights |
30/04/20 |
Exercise of Options and Total Voting Rights |
29/04/20 |
Holdings in Company |
28/04/20 |
Holdings in Company |
28/04/20 |
Supply Agreement with Clinton Health Access Initiative, Inc. |
27/04/20 |
CE-Mark of COVID-19 ELISA antibody test |
20/04/20 |
Material Transfer Agreement with Mologic on COVID-19 |
20/04/20 |
Holdings in Company |
16/04/20 |
Holdings in Company |
16/04/20 |
Holdings in Company |
14/04/20 |
Holdings in Company |
09/04/20 |
MOU on COVID-19 Consortium |
06/04/20 |
MSF Trial Publication |
06/04/20 |
Holding(s) in Company |
02/04/20 |
ODX Trading Update |
02/04/20 |
Chinese Approval for Food Detective Test |
24/01/20 |
Grant of Options |
17/01/19 |
VISITECT CD4 350 Nigeria MOH approval |
02/12/19 |
Interim Results - Year Ended 30 September 2019 |
02/12/19 |
Nigerian order for VISITECT CD4 |
25/11/19 |
Update on Allergy Test Menu |
21/11/19 |
Investor Briefing |
22/10/19 |
Result of AGM |
22/10/19 |
Trading Update and Notice of Interim Results |
15/10/19 |
Holding(s) in Company |
14/10/19 |
Holding(s) in Company |
14/10/19 |
Holding(s) in Company |
11/10/19 |
Holding(s) in Company |
10/10/19 |
Result of General Meeting |
27/09/19 |
Notice of AGM and posting of annual report |
23/09/19 |
Placing & Subscription and Notice of General Meeting |
23/09/19 |
Final Results – Year Ended 31 March 2019 |
16/09/19 |
Update on VISITECT® CD4 Advanced Disease test |
10/09/19 |
Purchase Order for Chinese Food Detective® test |
20/08/19 |
VISITECT CD4 Advanced Disease order |
16/08/19 |
Results, Trading Update & Nigerian CD4 Order |
06/06/19 |
Announcement of Results |
05/06/19 |
Holding(s) in Company |
03/06/19 |
Holding(s) in Company |
22/05/19 |
Subscription to raise c.£635,000 |
17/04/19 |
Trading Update |
18/03/19 |
CD4 Advanced Disease CE-Mark |
06/03/19 |
VISITECT CD4 Update |
01/03/19 |
Board Appointment |
29/01/19 |
VISITECT CD4 Advanced Disease Validation |
10/12/18 |
Directorate Change |
03/12/18 |
Interim Results - Six months ended 30 Sep 2018 |
19/10/18 |
Holding(s) in Company |
10/10/18 |
Trading Update |
27/09/18 |
Allersys CE Mark |
14/09/18 |
Result of AGM |
10/09/18 |
Holding(s) in Company |
06/06/18 |
FINAL RESULTS FOR THE YEAR ENDED 31 MARCH 2018 |
06/08/18 |
VISITECT® CD4 Advanced Disease Development Update |
18/07/18 |
VISITECT® CD4 commercialisation update |
02/07/18 |
Notice of Results - RNS |
28/06/18 |
Disposal of Infectious Disease Business |
21/05/18 |
VISITECT CD4 Update |
08/05/18 |
Allersys CE Mark |
02/05/18 |
Closure of Omega Diagnostics GmbH |
24/04/18 |
PDRM Dealing |
24/04/18 |
Holding(s) in Company |
23/04/18 |
Holding(s) in Company |
23/04/18 |
Director/PDMR Shareholding |
23/04/18 |
Holding(s) in Company |
23/04/18 |
Director/PDMR Shareholding |
20/04/18 |
Allersys Distributon Agreement |
10/04/18 |
Strategic Review of Operations and Trading Update |
10/04/18 |
Price Monitoring Extension |
12/01/18 |
Holding(s) in Company |
21/12/17 |
Allersys® CE-Mark |
14/12/17 |
CEO Succession |
29/11/17 |
VISITECT® CD4 CE-Mark |
01/11/17 |
Change of Registered Address |
23/10/17 |
Trading Update and Notice of Interim Results |
16/10/17 |
US Supply Agreement |
10/10/17 |
Holding(s) in Company |
05/09/17 |
Exercise of Options and Total Voting Rights |
29/08/17 |
Result of AGM |
18/07/17 |
Result of General Meeting |
17/07/17 |
Result of Open Offer |
06/07/17 |
Sale and leaseback of the building owned by Omega GmbH |
30/06/17 |
Result of Proposed Fundraising |